Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EBOVAC1

Financiado

Cerrado

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime Boost Re...

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime Boost Regimen Sofia ref. 115854 The overall aim of the EBOVAC programme is to assess the safety and efficacy of a novel prime boost prophylactic vaccine regimen against Ebola Virus Disease (EVD), which has been 100% effective in preclinical studies. This will be... ver más

30/11/2021

LSHTM

98M€

Presupuesto del proyecto: 98M€

Líder del proyecto

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICIN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-11-30

IMI2-2014-02-01: Vaccine development Phase I, II, an...

I+D

Cerrada hace 10 años

0% 60% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

LSHTM

47.21M€ | Lider

UNIVERSITY OF SIERRA LEONE

INSERM

653.72K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

VSV-EBOVAC Vaccine safety and immunogenicity signatures of human respon... 5M€ Cerrado

VSV-EBOPLUS SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV... 15M€ Cerrado

EBOVAC3 Bringing a prophylactic Ebola vaccine to licensure 51M€ Cerrado

EBOVAC2 Development of a Prophylactic Ebola Vaccine Using an Heterol... 51M€ Cerrado

VICI-DISEASE PROTECTION FROM VIRUSES WITH EPIDEMIC AND PANDEMIC DISEASE O... 8M€ Cerrado

EAVI2020 European AIDS Vaccine Initiative 2020 24M€ Cerrado

Duración del proyecto: 80 meses Fecha Inicio: 2015-03-05
Fecha Fin: 2021-11-30

Líder del proyecto

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICIN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 98M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The overall aim of the EBOVAC programme is to assess the safety and efficacy of a novel prime boost prophylactic vaccine regimen against Ebola Virus Disease (EVD), which has been 100% effective in preclinical studies. This will be done via phase I, II and III trials carried out in the EU and in Africa, in response to the urgent public health need raised by the current Ebola epidemic. To expedite the development of the vaccine regimen, Phase II and Phase III trials will be carried out in parallel and therefore co-ordinated by two separate teams. Proposals responding to IMI2 Topic 1 will consequently be split into two parts. EBOVAC1 will address the Phase I and Phase III trials, whereas EBOVAC2 will address the Phase II trials. EBOVAC1 will establish the initial safety and immunogenicity of the proposed heterologous prime/ boost regimen of Ad26.ZEBOV and MVA-BNFilo vaccine through phase I studies conducted in the UK, the US and currently Ebola- unaffected African countries. This will be done by administering the vaccine in different sequences and at different time intervals so as to identify the shortest schedule that is immunogenic and to maximize the potential for short term efficacy in affected countries. Initiation of these trials is expected to occur between December 2014 and March 2015 and approximately 300 subjects will be enrolled. The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine. This will be done by: 1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates (via WP4) 2. Carrying out Phase II trials in African and European volunteers in 6 countries, four in Africa and two in the EU with an overall target enrolment of approximately 1,500 subjects. Given the compressed nature of this development program, the Phase II studies will be conducted in parallel

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores